Publication Name	World Journal of Gastroenterology
Manuscript ID	29585
Country	Lebanon

Received	2016-08-24 10:47
Peer-Review Started	2016-08-25 15:04
To Make the First Decision	2016-09-05 14:17
Return for Revision	2016-09-07 10:53
Revised	2016-09-23 18:17
Second Decision	2016-10-25 20:02
Accepted by Journal Editor-in-Chief	2016-10-26 15:09
Accepted by Executive Editor-in-Chief	2016-10-31 15:05
Articles in Press	2016-10-31 15:05
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-12-02 14:11
Publish the Manuscript Online	2016-12-13 00:40

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
Manuscript Source	Invited Manuscript
All Author List	Marwan Ghosn, Tony Ibrahim, Tarek Assi, Elie El Rassy, Hampig Raphael Kourie and Joseph Kattan
Funding Agency and Grant Number
Corresponding Author	Marwan Ghosn, MD, Department of Oncology, Faculty of Medicine, Saint Joseph University, Alfred Naccache, Beirut 166830, Lebanon. marwanghosnmd@yahoo.com
Key Words	Review; Metastatic pancreatic cancer; FOLFIRINOX; Gemcitabine/nab-paclitaxel; Pivotal trials
Core Tip	This paper is a mini-review that compares the design of the two pivotal trials studying the role of FOLFIRINOX and gemcitabine/nab-Paclitaxel in the management of metastatic pancreatic cancer. It also analyzes the effects these regimens have on toxicity profile, quality of life, real life experiences, choice of second-line therapy and cost.
Publish Date	2016-12-13 00:40
Citation	Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J. dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(46): 10124-10130
URL	http://www.wjgnet.com/1007-9327/full/v22/i46/10124.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i46.10124

Full Article (PDF)	WJG-22-10124.pdf
Full Article (Word)	WJG-22-10124.doc
Manuscript File	29585-Review.docx
Answering Reviewers	29585-Answering reviewers.pdf
Audio Core Tip	29585-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	29585-Conflict-of-interest statement.pdf
Copyright License Agreement	29585-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	29585-Language certificate.pdf
Peer-review Report	29585-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	29585-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	29585-Scientific misconduct check.pdf
Scientific Editor Work List	29585-Scientific editor work list.pdf